Unity Biotechnology has raised $116 million more to fight diseases that originate from aging. The company plans to modify the human body’s cellular senescence — the process by which our cells age — to slow down aging and halt diseases

INVESTING IN UNITY

Some of humanity’s biggest investors have teamed up to fight diseases that come with aging.

San Francisco-based startup Unity Biotechnology has caught the attention of big investment firms and biotech venture capitalists recently. It’s been working on research with pharmaceutical potential for five years now, receiving initial funding from the likes of venture firm Arch Venture Partners.

Now, in a Series B round of venture capital investments, Unity was able to receive a hefty sum of $116 million. The sum was generated by investments from Fidelity Management and Research Company, Bezos Expeditions (Amazon founder Jeff Bezos’ investment arm), Partner Funds Management, Venrock, and Baillie Gifford. Wuxi and Mayo Clinic Ventures, already investors in Unity, also joined this deal.

CELLULAR SENESCENCE

Why the seemingly sudden interest in Unity?

A recent round of studies covering cellular senescence — or cellular aging (from the Latin senex, meaning old)  — have piqued the curiosity of scientists and investors alike. Research has identified how many of the diseases commonly associated with old age are products of cellular senescence…

source: futurism.com/fighting-agings-diseases-humanitys-biggest-investors-unite/